These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35036026)

  • 1. SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD.
    Septisetyani EP; Prasetyaningrum PW; Anam K; Santoso A
    Immune Netw; 2021 Dec; 21(6):e39. PubMed ID: 35036026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
    Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
    Front Immunol; 2021; 12():715464. PubMed ID: 34539645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
    Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
    J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Neutralizing Antibodies Against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudovirus-Based Assay.
    Almahboub SA; Algaissi A; Alfaleh MA; ElAssouli MZ; Hashem AM
    Front Microbiol; 2020; 11():2020. PubMed ID: 33013745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers.
    Ramos A; Cardoso MJ; Ribeiro L; Guimarães JT
    Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.
    Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G
    Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response.
    Mahmoud SA; Ganesan S; Naik S; Bissar S; Zamel IA; Warren KN; Zaher WA; Khan G
    Microbiol Spectr; 2021 Oct; 9(2):e0073321. PubMed ID: 34585943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
    Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
    Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Single-Round Infection Fluorescent SARS-CoV-2 Neutralization Test for COVID-19 Serological Testing at a Biosafety Level-2 Laboratory.
    Zou J; Xia H; Shi PY; Xie X; Ren P
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
    Valcourt EJ; Manguiat K; Robinson A; Chen JC; Dimitrova K; Philipson C; Lamoureux L; McLachlan E; Schiffman Z; Drebot MA; Wood H
    Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115294. PubMed ID: 33387896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2.
    Balinsky C; Jani V; Sun P; Williams M; Defang G; Porter KR
    Methods Mol Biol; 2022; 2452():361-378. PubMed ID: 35554917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses.
    Suhandynata RT; Bevins NJ; Tran JT; Huang D; Hoffman MA; Lund K; Kelner MJ; McLawhon RW; Gonias SL; Nemazee D; Fitzgerald RL
    medRxiv; 2021 Mar; ():. PubMed ID: 33758902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of a pseudovirus neutralization assay based on SARS-CoV-2 S protein incorporated into lentiviral particles.
    Wang S; Liu L; Wang C; Wang Z; Duan X; Chen G; Zhou H; Shao H
    Biosaf Health; 2022 Feb; 4(1):38-44. PubMed ID: 35005601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.
    Zhao G; Du L; Ma C; Li Y; Li L; Poon VK; Wang L; Yu F; Zheng BJ; Jiang S; Zhou Y
    Virol J; 2013 Aug; 10():266. PubMed ID: 23978242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
    Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
    Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay.
    Grenache DG; Ye C; Bradfute SB
    J Appl Lab Med; 2021 Mar; 6(2):491-495. PubMed ID: 33098417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trials.
    Sholukh AM; Fiore-Gartland A; Ford ES; Hou Y; Tse LV; Lempp FA; Kaiser H; Saint Germain R; Bossard E; Kee JJ; Diem K; Stuart AB; Rupert PB; Brock C; Buerger M; Doll MK; Randhawa AK; Stamatatos L; Strong RK; McLaughlin C; Jerome KR; Baric RS; Montefiori D; Corey L
    medRxiv; 2020 Dec; ():. PubMed ID: 33330875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays.
    Yu J; Li Z; He X; Gebre MS; Bondzie EA; Wan H; Jacob-Dolan C; Martinez DR; Nkolola JP; Baric RS; Barouch DH
    J Virol; 2021 May; 95(11):. PubMed ID: 33727331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples.
    Larsen SE; Berube BJ; Pecor T; Cross E; Brown BP; Williams BD; Johnson E; Qu P; Carter L; Wrenn S; Kepl E; Sydeman C; King NP; Baldwin SL; Coler RN
    J Immunol Methods; 2021 Dec; 499():113160. PubMed ID: 34599915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
    Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
    J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.